Tempus AI, Inc. $TEM Shares Bought by Aberdeen Group plc

Key Points

• Aberdeen Group boosted its stake in Tempus AI by 64.2% in Q4, adding 102,878 shares to hold 263,004 shares (about 0.15% of the company) valued at $15.53 million.
• Insider selling has been significant: the EVP and CFO recently sold roughly 11,000 shares each, and insiders sold 563,841 shares worth $32.26 million over the last quarter, though insiders still own 26.27% of the stock.
• Analysts are mixed but leaning positive: the consensus rating is a Moderate Buy with an average price target of $75.92, well above the recent trading price near $47.30, even as firms like Morgan Stanley and JPMorgan have trimmed targets.

Aberdeen Group plc grew its holdings in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 64.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 263,004 shares of the company's stock after purchasing an additional 102,878 shares during the period. Aberdeen Group plc owned approximately 0.15% of Tempus AI worth $15,530,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Tempus AI by 22.1% during the 3rd quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company's stock worth $762,032,000 after acquiring an additional 1,706,837 shares in the last quarter. Voloridge Investment Management LLC lifted its stake in Tempus AI by 183.0% in the 3rd quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company's stock valued at $129,708,000 after buying an additional 1,039,176 shares in the last quarter. Franklin Resources Inc. lifted its stake in Tempus AI by 0.4% in the 3rd quarter. Franklin Resources Inc. now owns 1,456,120 shares of the company's stock valued at $117,523,000 after buying an additional 5,375 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in Tempus AI by 312.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company's stock valued at $102,869,000 after buying an additional 965,730 shares in the last quarter. Finally, AQR Capital Management LLC lifted its stake in Tempus AI by 6.4% in the 3rd quarter. AQR Capital Management LLC now owns 904,872 shares of the company's stock valued at $73,032,000 after buying an additional 54,692 shares in the last quarter. Institutional investors and hedge funds own 24.22% of the company's stock.

Insider Buying and Selling at Tempus AI

In other news, EVP Andrew Polovin sold 10,949 shares of the company's stock in a transaction on Friday, February 20th. The stock was sold at an average price of $60.31, for a total transaction of $660,334.19. Following the completion of the sale, the executive vice president directly owned 126,918 shares in the company, valued at $7,654,424.58. This represents a 7.94% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO James William Rogers sold 10,084 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total value of $595,460.20. Following the completion of the sale, the chief financial officer owned 101,166 shares of the company's stock, valued at approximately $5,973,852.30. This represents a 9.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 563,841 shares of company stock worth $32,258,311. 26.27% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on TEM. Wall Street Zen lowered Tempus AI from a "hold" rating to a "sell" rating in a research note on Saturday, February 28th. Morgan Stanley reduced their price target on Tempus AI from $85.00 to $70.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 3rd. JPMorgan Chase & Co. reduced their price target on Tempus AI from $80.00 to $60.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 25th. Stifel Nicolaus set a $60.00 price target on Tempus AI in a research note on Wednesday, February 25th. Finally, Needham & Company LLC reissued a "buy" rating and set a $75.00 price target on shares of Tempus AI in a research note on Wednesday, March 11th. Eight equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $75.92.

Tempus AI Trading Down 0.2%

TEM stock opened at $47.30 on Tuesday. The company has a market cap of $8.46 billion, a price-to-earnings ratio of -33.55 and a beta of 4.90. The company has a quick ratio of 3.00, a current ratio of 3.13 and a debt-to-equity ratio of 2.52. The business has a fifty day simple moving average of $52.57 and a 200-day simple moving average of $67.87. Tempus AI, Inc. has a 52 week low of $36.22 and a 52 week high of $104.32.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.